Abaloparatide
Abaloparatide (PTHrP analogue)
Also known as: Tymlos
An FDA-approved bone-building peptide analogue of parathyroid hormone-related protein for postmenopausal osteoporosis.
Overview
Abaloparatide is a synthetic analogue of parathyroid hormone-related protein, approved as Tymlos to build bone in postmenopausal women at high fracture risk. Like teriparatide it stimulates new bone formation with once-daily injection, and trials showed strong fracture reduction. It is an established, approved peptide drug.
Mechanism of action
Selectively activates the PTH1 receptor to favor bone formation over resorption, increasing bone density.
Key studies & citations
- Human2016
Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial (ACTIVE)
2,463 women over 18 months: abaloparatide reduced new vertebral and nonvertebral fractures versus placebo with less hypercalcemia than teriparatide.
JAMA - Human2018
ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis
Over 43 months, vertebral fractures 0.9% versus 5.6% (84% relative risk reduction) for abaloparatide then alendronate.
Journal of Clinical Endocrinology and Metabolism
Frequently asked questions
How does abaloparatide compare to teriparatide?
Both are bone-building injectables. Abaloparatide is based on PTH-related protein and teriparatide on parathyroid hormone; both reduce fractures in high-risk patients.